Monte Rosa Therapeutics, Inc. (GLUE) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $129.88M | -42.1% |
| 2024 | $224.25M | +75.1% |
| 2023 | $128.10M | +133.3% |
| 2022 | $54.91M | -84.1% |
| 2021 | $346.07M | +729.9% |
| 2020 | $41.70M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $129.88M | -42.1% |
| 2024 | $224.25M | +75.1% |
| 2023 | $128.10M | +133.3% |
| 2022 | $54.91M | -84.1% |
| 2021 | $346.07M | +729.9% |
| 2020 | $41.70M | — |